Novo Nordisk's Wegovy weight-loss drug sales beat forecast, shares jump
Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring ...
Compounded Versions Of Weight Loss And Diabetes Drugs Led To Death And Hospitalization, Novo Nordisk Says It Is Aware
Novo Nordisk addresses safety concerns surrounding compounded versions of its weight-loss and diabetes drugs, including ...
Novo Nordisk Reports Strong Growth in 2024
Novo Nordisk ( (NVO) ) has released its Q3 earnings. Here is a breakdown of the information Novo Nordisk presented to its investors. Novo ...
Novo Nordisk posts Q3 sales of obesity drug Wegovy above forecast
Novo Nordisk on Wednesday reported better-than-expected quarterly sales of its popular Wegovy weight-loss drug and narrowed ...
Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts?
Novo Nordisk is expected to report third-quarter earnings on Wednesday. Stock up 8.55% in a year, 7.45% year-to-date.
Hims Reports Strong Earnings, Novo Nordisk Copycat Drug Coming in 2025
Hims & Hers Health reported third-quarter results that topped Street expectations Monday and said it plans to release a ...
Ozempic/Wegovy Maker Maintains Q3 Sales Growth On Booming Demand
On Wednesday, Novo Nordisk A/S (NYSE:NVO) reported third-quarter 2024 sales of 71.311 billion Danish kroner (around $10.3 ...